JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 21, 2006; DOI: 10.1124/jpet.106.105080


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.105080v1
319/1/468    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCluskie, K.
Right arrow Articles by Thomas, G R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCluskie, K.
Right arrow Articles by Thomas, G R.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


Received for publication March 24, 2006.
Revised July 17, 2006.
Accepted for publication July 20, 2006.

Phosphodiesterase type 4 inhibitors cause pro-inflammatory effects in vivo

Kerryn McCluskie 1*, Uwe Klein 1, Chris Linnevers 1, Yu-hua Ji 1, Alfred Yang 1, Craig Husfeld 1, G Roger Thomas 1

1 Theravance Inc.

* Address correspondence to: E-mail: mkerryn27{at}yahoo.co.uk

Abstract

PDE4 inhibitors are currently being evaluated as potential therapies for inflammatory airway diseases. However, this class of compounds has been shown to cause an arteritis/vasculitis of unknown etiology in rats and cynomolgus monkeys. Studies in rodents have demonstrated the anti-inflammatory effects of PDE4 inhibitors on LPS-induced airway inflammation. The aim of this work was to assess the direct effects of PDE4 inhibitors on inflammatory cells and cytokine levels in the lung in relation to therapeutic effects. The effects of the PDE4 inhibitors, roflumilast(3-cyclo-propylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) and piclamilast (3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide)), were assessed in vivo, using Balb/c mice, and in vitro, in un-stimulated human endothelial and epithelial cell lines. In Balb/c mice, LPS challenge caused an increase in neutrophils in BAL and lung tissue and BAL TNF-{alpha} levels, which were inhibited by treatment with either roflumilast or piclamilast (30-100 mg/kg, s.c.). However, roflumilast and piclamilast alone (100 mg/kg) caused a significant increase in plasma and lung tissue keratinocyte-derived chemokine (KC) levels, and lung tissue neutrophils. In vitro, both piclamilast and roflumilast caused an increase in IL-8 release from HUVEC but not BEAS-2B cells, suggesting that one source of the increased KC may be endothelial cells. At doses that antagonized an LPS-induced inflammatory response, the PDE4 inhibitors possessed pro-inflammatory activities in the lung that may limit their therapeutic potential. The pro-inflammatory cytokines KC and IL-8 therefore may provide surrogate biomarkers, both in pre-clinical animal models and in the clinic, to assess potential pro-inflammatory effects of this class of compounds.


Key words: LPS, chemokine, cytokine, inflammation, neutrophil, rodent





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.